Trial Outcomes & Findings for A Study To Evaluate Methods To Evaluate Back Pain (NCT NCT01045993)

NCT ID: NCT01045993

Last Updated: 2013-04-01

Results Overview

"First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon \& Lee.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

61 participants

Primary outcome timeframe

Baseline (time of wrap application or oral treatment administration) up to 4 hours

Results posted on

2013-04-01

Participant Flow

Participants were recruited who had primary muscular low back pain (in the Investigator's best judgment), which was atraumatic (no traumatic injury within 48 hours of enrollment) and not caused by, or related to, any clinically significant, medical diseases, whose onset had occurred within the past 3 months.

Eligible participants with at least moderate pain intensity on a 6-point categorical scale were randomized (N=61) to primary efficacy (heatwrap or oral placebo) or blinding groups ("sham" wrap or oral Ibuprofen). May have received rescue medication (oral acetaminophen) during the 4-hour evaluation period or at discharge after assessments completed.

Participant milestones

Participant milestones
Measure
ThermaCare®
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
Oral Placebo matching Oral IBU.
Overall Study
STARTED
26
5
5
25
Overall Study
COMPLETED
26
4
5
25
Overall Study
NOT COMPLETED
0
1
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
ThermaCare®
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
Oral Placebo matching Oral IBU.
Overall Study
Treated-later found eligibility not met
0
1
0
0

Baseline Characteristics

A Study To Evaluate Methods To Evaluate Back Pain

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Total
n=61 Participants
Total of all reporting groups
Age Continuous
30.0 years
STANDARD_DEVIATION 6.0 • n=99 Participants
25.6 years
STANDARD_DEVIATION 5.4 • n=107 Participants
30.0 years
STANDARD_DEVIATION 7.2 • n=206 Participants
28.8 years
STANDARD_DEVIATION 7.7 • n=157 Participants
29.1 years
STANDARD_DEVIATION 6.8 • n=390 Participants
Sex: Female, Male
Female
11 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
15 Participants
n=157 Participants
29 Participants
n=390 Participants
Sex: Female, Male
Male
15 Participants
n=99 Participants
4 Participants
n=107 Participants
3 Participants
n=206 Participants
10 Participants
n=157 Participants
32 Participants
n=390 Participants
Number of participants with categorical score for pain intensity
None=0
0 participants
n=99 Participants
0 participants
n=107 Participants
0 participants
n=206 Participants
0 participants
n=157 Participants
0 participants
n=390 Participants
Number of participants with categorical score for pain intensity
Mild=1
0 participants
n=99 Participants
0 participants
n=107 Participants
0 participants
n=206 Participants
0 participants
n=157 Participants
0 participants
n=390 Participants
Number of participants with categorical score for pain intensity
Moderate=2
19 participants
n=99 Participants
3 participants
n=107 Participants
2 participants
n=206 Participants
20 participants
n=157 Participants
44 participants
n=390 Participants
Number of participants with categorical score for pain intensity
Moderately severe=3
7 participants
n=99 Participants
1 participants
n=107 Participants
3 participants
n=206 Participants
4 participants
n=157 Participants
15 participants
n=390 Participants
Number of participants with categorical score for pain intensity
Severe=4
0 participants
n=99 Participants
1 participants
n=107 Participants
0 participants
n=206 Participants
1 participants
n=157 Participants
2 participants
n=390 Participants
Number of participants with categorical score for pain intensity
Extreme=5
0 participants
n=99 Participants
0 participants
n=107 Participants
0 participants
n=206 Participants
0 participants
n=157 Participants
0 participants
n=390 Participants
Back Stiffness Score
45.85 millimeters
STANDARD_DEVIATION 13.18 • n=99 Participants
55.00 millimeters
STANDARD_DEVIATION 18.71 • n=107 Participants
50.00 millimeters
STANDARD_DEVIATION 10.61 • n=206 Participants
51.24 millimeters
STANDARD_DEVIATION 20.32 • n=157 Participants
49.15 millimeters
STANDARD_DEVIATION 16.67 • n=390 Participants
Flexibility Assessment: Extension (Angle)
Maximum degrees
15.31 degree of angle
STANDARD_DEVIATION 4.53 • n=99 Participants
16.48 degree of angle
STANDARD_DEVIATION 4.82 • n=107 Participants
16.80 degree of angle
STANDARD_DEVIATION 3.89 • n=206 Participants
14.07 degree of angle
STANDARD_DEVIATION 4.51 • n=157 Participants
15.02 degree of angle
STANDARD_DEVIATION 4.48 • n=390 Participants
Flexibility Assessment: Extension (Angle)
Minus 5 degrees
10.19 degree of angle
STANDARD_DEVIATION 4.38 • n=99 Participants
11.26 degree of angle
STANDARD_DEVIATION 5.04 • n=107 Participants
11.62 degree of angle
STANDARD_DEVIATION 3.70 • n=206 Participants
9.01 degree of angle
STANDARD_DEVIATION 4.28 • n=157 Participants
9.91 degree of angle
STANDARD_DEVIATION 4.32 • n=390 Participants
Flexibility Assessment: Extension (Angle)
Plus 5 degrees (beyond maximum)
17.28 degree of angle
STANDARD_DEVIATION 4.48 • n=99 Participants
18.50 degree of angle
STANDARD_DEVIATION 2.24 • n=107 Participants
18.78 degree of angle
STANDARD_DEVIATION 4.35 • n=206 Participants
17.59 degree of angle
STANDARD_DEVIATION 4.02 • n=157 Participants
17.63 degree of angle
STANDARD_DEVIATION 4.08 • n=390 Participants
Flexibility Assessment: Extension (visual analog scale ([VAS])
VAS at Maximum degrees
48.65 millimeters
STANDARD_DEVIATION 15.69 • n=99 Participants
41.00 millimeters
STANDARD_DEVIATION 21.21 • n=107 Participants
48.20 millimeters
STANDARD_DEVIATION 13.52 • n=206 Participants
43.40 millimeters
STANDARD_DEVIATION 23.35 • n=157 Participants
45.84 millimeters
STANDARD_DEVIATION 19.26 • n=390 Participants
Flexibility Assessment: Extension (visual analog scale ([VAS])
VAS at Minus 5 degrees
33.54 millimeters
STANDARD_DEVIATION 19.41 • n=99 Participants
26.60 millimeters
STANDARD_DEVIATION 22.00 • n=107 Participants
34.00 millimeters
STANDARD_DEVIATION 11.51 • n=206 Participants
29.36 millimeters
STANDARD_DEVIATION 22.37 • n=157 Participants
31.30 millimeters
STANDARD_DEVIATION 20.11 • n=390 Participants
Flexibility Assessment: Extension (visual analog scale ([VAS])
VAS at Plus 5 degrees (beyond maximum)
56.92 millimeters
STANDARD_DEVIATION 20.27 • n=99 Participants
50.00 millimeters
STANDARD_DEVIATION 32.64 • n=107 Participants
59.40 millimeters
STANDARD_DEVIATION 14.28 • n=206 Participants
52.60 millimeters
STANDARD_DEVIATION 27.47 • n=157 Participants
54.79 millimeters
STANDARD_DEVIATION 23.78 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
L Maximum degrees
6.92 degree of angle
STANDARD_DEVIATION 1.69 • n=99 Participants
7.20 degree of angle
STANDARD_DEVIATION 1.79 • n=107 Participants
6.50 degree of angle
STANDARD_DEVIATION 2.40 • n=206 Participants
7.16 degree of angle
STANDARD_DEVIATION 1.50 • n=157 Participants
7.01 degree of angle
STANDARD_DEVIATION 1.65 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
R Maximum degrees
6.80 degree of angle
STANDARD_DEVIATION 1.76 • n=99 Participants
7.40 degree of angle
STANDARD_DEVIATION 1.34 • n=107 Participants
6.50 degree of angle
STANDARD_DEVIATION 2.06 • n=206 Participants
6.76 degree of angle
STANDARD_DEVIATION 1.80 • n=157 Participants
6.81 degree of angle
STANDARD_DEVIATION 1.74 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
L Minus 5 degrees
2.15 degree of angle
STANDARD_DEVIATION 1.19 • n=99 Participants
2.40 degree of angle
STANDARD_DEVIATION 1.34 • n=107 Participants
2.00 degree of angle
STANDARD_DEVIATION 1.41 • n=206 Participants
2.32 degree of angle
STANDARD_DEVIATION 1.07 • n=157 Participants
2.23 degree of angle
STANDARD_DEVIATION 1.15 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
R Minus 5 degrees
2.05 degree of angle
STANDARD_DEVIATION 1.27 • n=99 Participants
2.40 degree of angle
STANDARD_DEVIATION 1.34 • n=107 Participants
1.80 degree of angle
STANDARD_DEVIATION 1.64 • n=206 Participants
1.92 degree of angle
STANDARD_DEVIATION 1.19 • n=157 Participants
2.00 degree of angle
STANDARD_DEVIATION 1.25 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
L Plus 5 degrees (beyond maximum)
7.22 degree of angle
STANDARD_DEVIATION 1.66 • n=99 Participants
7.40 degree of angle
STANDARD_DEVIATION 1.34 • n=107 Participants
6.60 degree of angle
STANDARD_DEVIATION 2.19 • n=206 Participants
7.42 degree of angle
STANDARD_DEVIATION 1.40 • n=157 Participants
7.26 degree of angle
STANDARD_DEVIATION 1.56 • n=390 Participants
Flexibility Assessment: Side-to-Side (Angle)
R Plus 5 degrees (beyond maximum)
7.33 degree of angle
STANDARD_DEVIATION 1.41 • n=99 Participants
7.70 degree of angle
STANDARD_DEVIATION 0.67 • n=107 Participants
7.00 degree of angle
STANDARD_DEVIATION 1.39 • n=206 Participants
7.02 degree of angle
STANDARD_DEVIATION 1.68 • n=157 Participants
7.20 degree of angle
STANDARD_DEVIATION 1.47 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
L VAS at Maximum degrees
42.69 millimeters
STANDARD_DEVIATION 22.61 • n=99 Participants
32.40 millimeters
STANDARD_DEVIATION 14.64 • n=107 Participants
43.60 millimeters
STANDARD_DEVIATION 21.28 • n=206 Participants
35.24 millimeters
STANDARD_DEVIATION 25.87 • n=157 Participants
38.87 millimeters
STANDARD_DEVIATION 23.29 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
R VAS at Maximum degrees
47.38 millimeters
STANDARD_DEVIATION 25.18 • n=99 Participants
40.40 millimeters
STANDARD_DEVIATION 20.97 • n=107 Participants
52.20 millimeters
STANDARD_DEVIATION 14.45 • n=206 Participants
45.40 millimeters
STANDARD_DEVIATION 20.69 • n=157 Participants
46.39 millimeters
STANDARD_DEVIATION 22.03 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
L VAS at Minus 5 degrees
24.85 millimeters
STANDARD_DEVIATION 22.82 • n=99 Participants
15.20 millimeters
STANDARD_DEVIATION 9.47 • n=107 Participants
28.20 millimeters
STANDARD_DEVIATION 14.46 • n=206 Participants
22.80 millimeters
STANDARD_DEVIATION 18.77 • n=157 Participants
23.49 millimeters
STANDARD_DEVIATION 19.66 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
R VAS at Minus 5 degrees
24.35 millimeters
STANDARD_DEVIATION 19.57 • n=99 Participants
19.80 millimeters
STANDARD_DEVIATION 13.92 • n=107 Participants
34.00 millimeters
STANDARD_DEVIATION 19.96 • n=206 Participants
24.96 millimeters
STANDARD_DEVIATION 18.75 • n=157 Participants
25.02 millimeters
STANDARD_DEVIATION 18.68 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
L VAS at Plus 5 degrees (beyond maximum)
40.58 millimeters
STANDARD_DEVIATION 26.10 • n=99 Participants
27.80 millimeters
STANDARD_DEVIATION 15.42 • n=107 Participants
48.20 millimeters
STANDARD_DEVIATION 22.83 • n=206 Participants
37.64 millimeters
STANDARD_DEVIATION 25.93 • n=157 Participants
38.95 millimeters
STANDARD_DEVIATION 24.95 • n=390 Participants
Flexibility Assessment: Side-to-side (VAS)
R VAS at Plus 5 degrees (beyond maximum)
48.42 millimeters
STANDARD_DEVIATION 26.16 • n=99 Participants
42.40 millimeters
STANDARD_DEVIATION 22.03 • n=107 Participants
55.60 millimeters
STANDARD_DEVIATION 13.63 • n=206 Participants
44.92 millimeters
STANDARD_DEVIATION 21.85 • n=157 Participants
47.08 millimeters
STANDARD_DEVIATION 23.05 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
L Maximum degrees
15.67 degree of angle
STANDARD_DEVIATION 4.08 • n=99 Participants
17.36 degree of angle
STANDARD_DEVIATION 3.77 • n=107 Participants
15.96 degree of angle
STANDARD_DEVIATION 6.44 • n=206 Participants
17.03 degree of angle
STANDARD_DEVIATION 4.40 • n=157 Participants
16.39 degree of angle
STANDARD_DEVIATION 4.35 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
R Maximum degrees
16.78 degree of angle
STANDARD_DEVIATION 4.73 • n=99 Participants
16.66 degree of angle
STANDARD_DEVIATION 4.26 • n=107 Participants
16.62 degree of angle
STANDARD_DEVIATION 6.19 • n=206 Participants
16.91 degree of angle
STANDARD_DEVIATION 4.78 • n=157 Participants
16.81 degree of angle
STANDARD_DEVIATION 4.71 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
L Minus 5 degrees
10.21 degree of angle
STANDARD_DEVIATION 4.12 • n=99 Participants
11.30 degree of angle
STANDARD_DEVIATION 4.09 • n=107 Participants
10.42 degree of angle
STANDARD_DEVIATION 6.19 • n=206 Participants
11.46 degree of angle
STANDARD_DEVIATION 4.33 • n=157 Participants
10.83 degree of angle
STANDARD_DEVIATION 4.31 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
R Minus 5 degrees
11.27 degree of angle
STANDARD_DEVIATION 4.48 • n=99 Participants
11.28 degree of angle
STANDARD_DEVIATION 4.38 • n=107 Participants
10.74 degree of angle
STANDARD_DEVIATION 6.12 • n=206 Participants
11.56 degree of angle
STANDARD_DEVIATION 4.46 • n=157 Participants
11.34 degree of angle
STANDARD_DEVIATION 4.49 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
L Plus 5 degrees (beyond maximum)
17.95 degree of angle
STANDARD_DEVIATION 3.28 • n=99 Participants
17.66 degree of angle
STANDARD_DEVIATION 3.73 • n=107 Participants
17.12 degree of angle
STANDARD_DEVIATION 5.13 • n=206 Participants
18.24 degree of angle
STANDARD_DEVIATION 4.12 • n=157 Participants
17.98 degree of angle
STANDARD_DEVIATION 3.75 • n=390 Participants
Flexibility Assessment: Rotation (Angle)
R Plus 5 degrees (beyond maximum)
18.48 degree of angle
STANDARD_DEVIATION 4.14 • n=99 Participants
18.46 degree of angle
STANDARD_DEVIATION 3.73 • n=107 Participants
18.06 degree of angle
STANDARD_DEVIATION 4.39 • n=206 Participants
18.32 degree of angle
STANDARD_DEVIATION 4.30 • n=157 Participants
18.38 degree of angle
STANDARD_DEVIATION 4.10 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
L VAS at Maximum degrees
52.54 millimeters
STANDARD_DEVIATION 23.88 • n=99 Participants
60.00 millimeters
STANDARD_DEVIATION 23.74 • n=107 Participants
60.60 millimeters
STANDARD_DEVIATION 12.30 • n=206 Participants
48.80 millimeters
STANDARD_DEVIATION 23.41 • n=157 Participants
52.28 millimeters
STANDARD_DEVIATION 22.81 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
R VAS at Maximum degrees
51.65 millimeters
STANDARD_DEVIATION 21.33 • n=99 Participants
59.40 millimeters
STANDARD_DEVIATION 31.09 • n=107 Participants
61.60 millimeters
STANDARD_DEVIATION 15.84 • n=206 Participants
49.64 millimeters
STANDARD_DEVIATION 25.97 • n=157 Participants
52.28 millimeters
STANDARD_DEVIATION 23.56 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
L VAS at Minus 5 degrees
36.92 millimeters
STANDARD_DEVIATION 21.25 • n=99 Participants
47.20 millimeters
STANDARD_DEVIATION 22.94 • n=107 Participants
46.60 millimeters
STANDARD_DEVIATION 21.24 • n=206 Participants
33.24 millimeters
STANDARD_DEVIATION 22.28 • n=157 Participants
37.05 millimeters
STANDARD_DEVIATION 21.77 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
R VAS at Minus 5 degrees
38.15 millimeters
STANDARD_DEVIATION 22.26 • n=99 Participants
44.20 millimeters
STANDARD_DEVIATION 27.47 • n=107 Participants
47.40 millimeters
STANDARD_DEVIATION 15.84 • n=206 Participants
36.56 millimeters
STANDARD_DEVIATION 25.02 • n=157 Participants
38.75 millimeters
STANDARD_DEVIATION 23.12 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
L VAS at Plus 5 degrees (beyond maximum)
56.62 millimeters
STANDARD_DEVIATION 25.62 • n=99 Participants
63.80 millimeters
STANDARD_DEVIATION 18.79 • n=107 Participants
65.80 millimeters
STANDARD_DEVIATION 12.19 • n=206 Participants
49.24 millimeters
STANDARD_DEVIATION 22.12 • n=157 Participants
54.93 millimeters
STANDARD_DEVIATION 23.10 • n=390 Participants
Flexibility Assessment: Rotation (VAS)
R VAS at Plus 5 degrees (beyond maximum)
59.12 millimeters
STANDARD_DEVIATION 27.10 • n=99 Participants
66.40 millimeters
STANDARD_DEVIATION 28.17 • n=107 Participants
64.20 millimeters
STANDARD_DEVIATION 11.50 • n=206 Participants
50.92 millimeters
STANDARD_DEVIATION 26.61 • n=157 Participants
56.77 millimeters
STANDARD_DEVIATION 26.08 • n=390 Participants

PRIMARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 4 hours

Population: Intent-to-treat population (ITT): all randomized participants who applied/dosed with study product and had a baseline assessment. Median and/or upper limit of CI reported as 240 minutes if \>240 minutes. No primary endpoint was prespecified in this Pilot study; 1 key efficacy endpoint was selected for reporting purposes only.

"First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon \& Lee.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Time to First Perceptible Relief (Confirmed by Meaningful Relief)
96.5 minutes
Interval 26.4 to 240.0
38.7 minutes
Interval 7.5 to 240.0
54.0 minutes
Interval 31.3 to 240.0
240 minutes
CI was not calculated as time to first perceptible pain relief was \>240 minutes.

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 4 hours

Population: ITT population. Median and/or upper limit of CI reported as 240 minutes if median or upper limit \>240 minutes.

Time to "meaningful relief" defined as elapsed time from start of treatment until participant depressed the second stopwatch indicating "meaningful relief" (meaningful to participant). Participant consider censored if participant did not depress the stopwatch by end of 4-hour in-patient evaluation, or became a treatment failure (rescue or discontinuation) during the time prior to depressing the second stopwatch. Censoring was at time of dropout if participant withdrew for non-efficacy related reasons during the 4-hour in-patient portion of the study. CI calculated using method of Simon \& Lee.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Time to Meaningful Relief
215.7 minutes
Interval 163.7 to 240.0
104.0 minutes
Interval 71.0 to 240.0
135.1 minutes
Interval 119.8 to 240.0
240 minutes
CI was not calculated as time to meaningful pain relief was \>240 minutes.

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 8 hours

Population: ITT population.

TOTPAR 0-8 sum of pain relief from 0 through 8 hours, weighted by the time duration between the current timepoint and the previous timepoint. Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief. Total possible score 0 to 40; higher score indicated better relief.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Time Weighted Sum of Pain Relief From 0 Through 8 Hours (TOTPAR 0-8)
22.0 scores on a scale
Standard Deviation 7.9
15.6 scores on a scale
Standard Deviation 13.1
17.0 scores on a scale
Standard Deviation 13.5
11.5 scores on a scale
Standard Deviation 10.0

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 8 hours

Population: ITT population.

Time weighted sum of change calculated as sum of change from baseline in back stiffness scores from 0 through 8 hours, weighted by time duration between current timepoint and previous timepoint. Based on hourly (from baseline) back stiffness assessment rating from 0 (no muscle stiffness) to 100 (most possible muscle stiffness). Sum of change derived by subtracting score at post-dosing time point from baseline score. Total possible score -800 to 800; higher positive value was indicative of greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Time Weighted Sum of Change From Baseline in the Back Stiffness Score Over 8 Hours
167.0 scores on a scale
Standard Deviation 83.7
140.6 scores on a scale
Standard Deviation 71.3
105.0 scores on a scale
Standard Deviation 143.2
74.5 scores on a scale
Standard Deviation 111.3

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 8 hours

Population: ITT population. Time to treatment failure not calculable as there were no treatment failures in this study. No participants required use of rescue medication or discontinued study prior to 8 hour evaluation.

Time to treatment failure defined as time from dosing to the time of rescue medication within the scheduled duration of the study (8 hours); or for participants who withdrew from the study due to lack of efficacy without taking rescue medication, the time of the last assessment was considered the time to treatment failure; or if participant did not take rescue medication, or did not discontinue due to lack of efficacy, the time to treatment failure was considered censored at 8 hours (the scheduled duration of the study).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes

Population: ITT population.

Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Individual Time-Point Pain Relief Scores
420 minutes
3.1 scores on a scale
Standard Deviation 1.4
2.0 scores on a scale
Standard Deviation 2.1
2.6 scores on a scale
Standard Deviation 2.4
1.7 scores on a scale
Standard Deviation 1.6
Individual Time-Point Pain Relief Scores
60 minutes
1.4 scores on a scale
Standard Deviation 1.1
1.0 scores on a scale
Standard Deviation 0.7
1.0 scores on a scale
Standard Deviation 1.4
0.6 scores on a scale
Standard Deviation 1.1
Individual Time-Point Pain Relief Scores
120 minutes
2.1 scores on a scale
Standard Deviation 1.1
1.6 scores on a scale
Standard Deviation 1.3
1.6 scores on a scale
Standard Deviation 1.5
1.2 scores on a scale
Standard Deviation 1.3
Individual Time-Point Pain Relief Scores
180 minutes
2.9 scores on a scale
Standard Deviation 1.2
2.2 scores on a scale
Standard Deviation 1.9
2.4 scores on a scale
Standard Deviation 1.5
1.4 scores on a scale
Standard Deviation 1.4
Individual Time-Point Pain Relief Scores
240 minutes
3.0 scores on a scale
Standard Deviation 1.2
2.2 scores on a scale
Standard Deviation 1.9
2.4 scores on a scale
Standard Deviation 1.8
1.7 scores on a scale
Standard Deviation 1.5
Individual Time-Point Pain Relief Scores
300 minutes
3.1 scores on a scale
Standard Deviation 1.2
2.0 scores on a scale
Standard Deviation 2.0
2.2 scores on a scale
Standard Deviation 1.8
1.5 scores on a scale
Standard Deviation 1.5
Individual Time-Point Pain Relief Scores
360 minutes
3.2 scores on a scale
Standard Deviation 1.2
2.4 scores on a scale
Standard Deviation 1.8
2.4 scores on a scale
Standard Deviation 2.3
1.7 scores on a scale
Standard Deviation 1.5
Individual Time-Point Pain Relief Scores
480 minutes
3.2 scores on a scale
Standard Deviation 1.4
2.2 scores on a scale
Standard Deviation 1.9
2.4 scores on a scale
Standard Deviation 2.2
1.7 scores on a scale
Standard Deviation 1.5

SECONDARY outcome

Timeframe: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes

Population: ITT population.

Low back muscle stiffness rated hourly (from baseline) by the participant by placing a line on a visual analog scale (VAS) from 0 millimeters (mm) to 100 mm in length with 0=no muscle stiffness up to 100 (most possible stiffness).

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in Individual Time-point Back Stiffness Scores
480 minutes
26.3 scores on a scale
Standard Deviation 15.8
20.4 scores on a scale
Standard Deviation 10.6
14.0 scores on a scale
Standard Deviation 26.1
12.0 scores on a scale
Standard Deviation 17.1
Change From Baseline in Individual Time-point Back Stiffness Scores
60 minutes
9.4 scores on a scale
Standard Deviation 10.8
8.4 scores on a scale
Standard Deviation 10.5
-3.0 scores on a scale
Standard Deviation 8.4
1.3 scores on a scale
Standard Deviation 11.8
Change From Baseline in Individual Time-point Back Stiffness Scores
120 minutes
14.7 scores on a scale
Standard Deviation 10.4
17.6 scores on a scale
Standard Deviation 10.3
8.0 scores on a scale
Standard Deviation 12.5
4.7 scores on a scale
Standard Deviation 11.5
Change From Baseline in Individual Time-point Back Stiffness Scores
180 minutes
20.3 scores on a scale
Standard Deviation 11.8
18.6 scores on a scale
Standard Deviation 12.8
14.0 scores on a scale
Standard Deviation 18.5
8.9 scores on a scale
Standard Deviation 24.2
Change From Baseline in Individual Time-point Back Stiffness Scores
240 minutes
22.7 scores on a scale
Standard Deviation 12.2
17.6 scores on a scale
Standard Deviation 12.1
18.0 scores on a scale
Standard Deviation 20.2
14.0 scores on a scale
Standard Deviation 23.2
Change From Baseline in Individual Time-point Back Stiffness Scores
300 minutes
23.5 scores on a scale
Standard Deviation 11.8
19.2 scores on a scale
Standard Deviation 11.0
18.0 scores on a scale
Standard Deviation 20.2
9.6 scores on a scale
Standard Deviation 17.4
Change From Baseline in Individual Time-point Back Stiffness Scores
360 minutes
24.5 scores on a scale
Standard Deviation 13.1
20.8 scores on a scale
Standard Deviation 10.6
18.0 scores on a scale
Standard Deviation 22.0
11.5 scores on a scale
Standard Deviation 17.8
Change From Baseline in Individual Time-point Back Stiffness Scores
420 minutes
25.8 scores on a scale
Standard Deviation 15.7
18.0 scores on a scale
Standard Deviation 10.4
18.0 scores on a scale
Standard Deviation 28.0
12.5 scores on a scale
Standard Deviation 17.1

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum extension (as if performing a sit-up) of 20 degrees movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees minus 5, and x degrees plus 5. Flexibility score derived using standardized value and VAS score (participant rating of pain by marking level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for extension flexibility were average of the extension flexibility data on the combined score (range -66 to 552); higher value indicated greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline (Bsl) in Combined Flexibility Score: Extension
At Maximum degrees
13.7 scores on a scale
Standard Deviation 34.8
-4.1 scores on a scale
Standard Deviation 35.6
12.7 scores on a scale
Standard Deviation 23.1
4.3 scores on a scale
Standard Deviation 23.3
Change From Baseline (Bsl) in Combined Flexibility Score: Extension
At Minus 5 degrees
17.7 scores on a scale
Standard Deviation 39.1
8.4 scores on a scale
Standard Deviation 43.2
8.0 scores on a scale
Standard Deviation 39.7
39.0 scores on a scale
Standard Deviation 133.6
Change From Baseline (Bsl) in Combined Flexibility Score: Extension
At Plus 5 degrees (beyond maximum)
15.8 scores on a scale
Standard Deviation 36.4
-5.8 scores on a scale
Standard Deviation 31.6
9.3 scores on a scale
Standard Deviation 30.9
1.5 scores on a scale
Standard Deviation 17.7

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum side-to-side movement of plus or minus (+/-) 10 degrees for left, and right (L, R), movement. Angle at Bsl and 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain to 100=worst pain). Final derived data for overall flexibility was the average of side-to-side (L, R) flexibility data on the combined score (range -81 to 264); higher value=greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side
At Maximum degrees
13.9 scores on a scale
Standard Deviation 28.7
14.0 scores on a scale
Standard Deviation 27.2
3.8 scores on a scale
Standard Deviation 21.6
0.7 scores on a scale
Standard Deviation 21.7
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side
At Minus 5 degrees
9.5 scores on a scale
Standard Deviation 37.3
2.3 scores on a scale
Standard Deviation 2.8
-18.0 scores on a scale
Standard Deviation 38.0
14.2 scores on a scale
Standard Deviation 65.5
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side
At Plus 5 degrees (beyond maximum)
11.0 scores on a scale
Standard Deviation 32.5
14.8 scores on a scale
Standard Deviation 31.3
10.9 scores on a scale
Standard Deviation 25.1
2.0 scores on a scale
Standard Deviation 14.5

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum rotation at waist of plus or minus (+/-) 30 degrees for left, and right (L, R), movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for overall flexibility were the average of rotation (L, R) flexibility data on combined score (range -80 to 155); higher value=greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation
At Maximum degrees
9.9 scores on a scale
Standard Deviation 19.0
24.1 scores on a scale
Standard Deviation 12.5
12.1 scores on a scale
Standard Deviation 18.5
-0.2 scores on a scale
Standard Deviation 16.4
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation
At Minus 5 degrees
13.0 scores on a scale
Standard Deviation 33.3
35.9 scores on a scale
Standard Deviation 22.0
6.8 scores on a scale
Standard Deviation 21.5
4.1 scores on a scale
Standard Deviation 42.9
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation
At Plus 5 degrees (beyond maximum)
10.0 scores on a scale
Standard Deviation 22.2
33.4 scores on a scale
Standard Deviation 27.2
14.5 scores on a scale
Standard Deviation 19.8
-1.4 scores on a scale
Standard Deviation 13.9

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement of 20 degrees for extension (as if performing a sit-up) to the degree of movement at which participant perceives discomfort or pain. Higher score indicated greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Extension
1.4 degrees
Standard Deviation 3.0
-1.1 degrees
Standard Deviation 3.1
0.5 degrees
Standard Deviation 2.9
1.2 degrees
Standard Deviation 4.6

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement +/- 10 degrees for left, and right, side-to-side movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right side-to-side scores. Higher score indicated greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Side-to-Side
0.1 degrees
Standard Deviation 1.2
0.4 degrees
Standard Deviation 1.0
-0.3 degrees
Standard Deviation 0.4
-0.2 degrees
Standard Deviation 1.4

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum rotation at waist of +/- 30 degrees for left, and right, movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right rotation scores. Higher score indicated greater improvement.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Rotation
0.6 degrees
Standard Deviation 2.5
1.3 degrees
Standard Deviation 1.4
-0.6 degrees
Standard Deviation 0.6
-0.6 degrees
Standard Deviation 3.3

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum extension of 20 degrees movement (as if performing a sit-up). When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Higher score indicated greater discomfort/pain.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension
At Minus 5 degrees
2.7 scores on a scale
Standard Deviation 15.1
7.4 scores on a scale
Standard Deviation 24.7
7.2 scores on a scale
Standard Deviation 23.3
-1.8 scores on a scale
Standard Deviation 17.8
Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension
At Maximum degrees
4.7 scores on a scale
Standard Deviation 25.0
-0.8 scores on a scale
Standard Deviation 32.9
10.4 scores on a scale
Standard Deviation 15.4
-0.6 scores on a scale
Standard Deviation 11.0
Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension
At Plus 5 degrees (beyond maximum)
9.5 scores on a scale
Standard Deviation 24.7
-5.6 scores on a scale
Standard Deviation 32.1
12.6 scores on a scale
Standard Deviation 30.7
2.0 scores on a scale
Standard Deviation 11.5

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum side-to-side movement of +/- 10 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side
At Maximum degrees
7.9 scores on a scale
Standard Deviation 13.4
5.0 scores on a scale
Standard Deviation 10.9
6.6 scores on a scale
Standard Deviation 21.2
-0.3 scores on a scale
Standard Deviation 15.4
Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side
At Minus 5 degrees
4.2 scores on a scale
Standard Deviation 10.7
4.6 scores on a scale
Standard Deviation 5.8
2.2 scores on a scale
Standard Deviation 18.3
2.6 scores on a scale
Standard Deviation 10.4
Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side
At Plus 5 degrees (beyond maximum)
5.9 scores on a scale
Standard Deviation 18.1
7.3 scores on a scale
Standard Deviation 16.0
11.2 scores on a scale
Standard Deviation 25.4
0.9 scores on a scale
Standard Deviation 12.7

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) and 4 hours

Population: ITT population.

Flexibility assessed using Paris Plinth table with maximum rotation at waist of +/- 30 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Change From Baseline in Pain Measurement for Flexibility Measure: Rotation
At Plus 5 degrees (beyond maximum)
9.3 scores on a scale
Standard Deviation 21.5
25.4 scores on a scale
Standard Deviation 14.1
20.9 scores on a scale
Standard Deviation 18.1
-1.2 scores on a scale
Standard Deviation 12.0
Change From Baseline in Pain Measurement for Flexibility Measure: Rotation
At Maximum degrees
7.4 scores on a scale
Standard Deviation 15.9
17.4 scores on a scale
Standard Deviation 9.0
15.7 scores on a scale
Standard Deviation 18.9
0.2 scores on a scale
Standard Deviation 13.5
Change From Baseline in Pain Measurement for Flexibility Measure: Rotation
At Minus 5 degrees
5.4 scores on a scale
Standard Deviation 17.8
19.4 scores on a scale
Standard Deviation 8.4
12.5 scores on a scale
Standard Deviation 15.6
3.2 scores on a scale
Standard Deviation 13.5

SECONDARY outcome

Timeframe: Baseline (time of wrap application or oral treatment administration) up to 8 hours

Population: ITT population.

At hour 8, or at the time of rescue, if it occurred, participants performed a global assessment in their diary in response to the question: How would you rate the study treatment as a pain reliever? Very Poor=0, Poor=1, Fair=2, Good=3, Very Good=4, Excellent=5.

Outcome measures

Outcome measures
Measure
ThermaCare®
n=26 Participants
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 Participants
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Oral Ibuprofen (IBU)
n=5 Participants
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 Participants
Oral Placebo matching Oral IBU.
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Very poor=0
0 participants
1 participants
0 participants
6 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Poor=1
0 participants
0 participants
1 participants
5 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Fair=2
4 participants
0 participants
1 participants
10 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Good=3
10 participants
2 participants
2 participants
1 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Very good=4
9 participants
0 participants
1 participants
1 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Excellent=5
2 participants
0 participants
0 participants
2 participants
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Response missing
1 participants
2 participants
0 participants
0 participants

Adverse Events

Oral Ibuprofen (IBU)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Oral Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

ThermaCare®

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Sham Wrap (Inactive)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Oral Ibuprofen (IBU)
n=5 participants at risk
IBU (commercially available Advil®) administered as two 200 milligram (mg) tablets by mouth (PO) as a one time dose.
Oral Placebo
n=25 participants at risk
Oral Placebo matching Oral IBU.
ThermaCare®
n=26 participants at risk
Active treatment low back/hip heatwrap administered one time (could be applied for up to 8 hours); applied within 5 minutes of unsealing the foil wrapper.
Sham Wrap (Inactive)
n=5 participants at risk
Inactive heatwrap administered one time as a non-heating wrap; applied within 5 minutes of unsealing the foil wrapper.
Nervous system disorders
Headache
0.00%
0/5 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
0.00%
0/25 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
7.7%
2/26 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
0.00%
0/5 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders
Asthma
0.00%
0/5 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
0.00%
0/25 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
3.8%
1/26 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
0.00%
0/5 • Baseline up to 5 days after the 8 hour evaluation period.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after the disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
  • Publication restrictions are in place

Restriction type: OTHER